Although many studies have been reported on respiratory immunization with live virus vaccines, the effectiveness of parenteral and respiratory immunization was not always compared. In nearly all cases only one method of respiratory immunization was used, either aerosol exposure (19) or intranasal (i.n.) instillation (5, 16, 21, 27, 28) .
Immunization of mice against encephalomyocarditis (EMC) virus was one of the models used for respiratory vaccination. Aerosol immunization with the attenuated A-37 Mengo virus strain has been reported by Prato and Akers (19) . Peroral immunization with a tissue culture strain of EMC virus (13) was shown to protect mice against infection with a fully virnlent EMC virus strain. In a previous communication (4) (1), mice received the vaccine by the respiratory route since only mouth and nose were exposed to the aerosol. The exposure time was 15 min; the relative humidity was 60 to 70%. The aerosol was sampled by means of an all-glass impinger (1), and the inhaled vaccine dose was estimated assuming a mean respiratory volume for mice of 25 ml/min (14) .
Serum collection and antibody determinations. Twenty days after immunization and 3 weeks after challenge the mice were bled. Hemagglutination inhibition tests were carried out as described previously (4) .
Statistics. From survival data mean effective doses (ED50) were calculated by the method of probit analysis (12) . Geometric mean antibody titers were calculated from serum titers of individual mice.
Experimental design. Groups of 10 mice were immunized by graded doses of vaccine. In each experiment 10 control mice were given phosphate-buffered saline instead of vaccine. Protection was evaluated by i.p. injection of 200 mean lethal doses or by (LD50) i.n. instillation of 1,000 LD50 of large-plaqueforming (LPF) EMC virus 21 days after immunization. None of the control mice survived challenge.
Mice were observed for at least 4 weeks after challenge.
RESULTS
Development of serum antibody titers after i.p. immunization. Forty mice received 2.5 x 106 plaque-forming units (PFU) of live MPF virus by i.p. injection. At various time intervals, groups of four animals were sacrificed and bled by heart puncture. The sera were stored at -20 C and later assayed simultaneously for antibodies. The development of these titers is shown in Fig. 1 . After 3 days no antibodies are detectable, after 5 days the antibody level is sufficiently high so that all animals would be protected, the protective ED50 being 1.0 hemagglutination inhibiting unit (HAIU)/ml as described previously (4). After 100 HAIU/ml, so that all animals would still survive challenge. Immunization of mice with MPF virus thus appears to be possible; the protective ED50 being much less than 2.5 x 106 PFU/animal. ED50 determinations: intraperitoneal immunization. For i.p. immunization experiments, five groups of 10 mice were used. Figure  2A shows the relationship between vaccine dose and survival after i.p. challenge. The calculated regression line is plotted together with the percentage of survival. From three experiments the combined ED50 value was calculated and appeared to be 607 PFU; its 95% confidence limits are 422 and 884 PFU.
Respiratory immunization: aerosol treatment. Five groups of 10 mice were exposed to aerosols of MPF EMC virus. The survival after i.p. challenge as a function of vaccine dose is shown in Fig. 2B . The ED50 corresponds to approximately 2,300 PFU of virus, which is roughly four times as much as the i.p. ED50.
Intratracheal injection. To five groups of 10 mice the vaccine was administered by i.t. instillation. The ED50 value appeared to be approximately 200 PFU and is lower than its i.p. counterpart. A second experiment yielded similar results. Figure 2C shows the protective effect in relation to the antigen dose.
Intranasal instillation. Five groups of 10 mice received the vaccine by i.n. instillation. Figure 2E shows the survival rates after i. Protection against intranasal challenge. To investigate whether local immune reactions play an important role in protection against respiratory EMC virus infections, five groups of 10 mice were immunized by i.p. injection and five other groups were immunized by i.n. instillation. All animals were challenged with 1,000 i.n. LD50; the i.n. LD50 was measured in a previous experiment and appeared to be 548 PFU of LPF virus. The survival after i.n. challenge is shown in Fig. 2D and F Fig. 3 and for i.n. immunization in Fig. 4 . The secondary responses after both i.n. and i.p. challenge are also indicated. The titers are low in comparison with those shown in Fig. 1 where a much higher vaccine dose was used. A vaccine dose equal to the ED50 value will evoke a serum antibody titer of about 5 HAIU after i.n. and also after i.p. administration. In both cases, i.n. and i.p. challenge will lead to 50% survival. This means that, in all combinations, the survival rate depends on the serum antibody titer and is not enhanced by local defense mechanisms, which could be active after i.n. immunization followed by i.n. challenge.
DISCUSSION
From the slope of the dose response curves ( Fig. 3 and 4) , which is about 450, it appears that the serum titer of a group depends on the injected dose of live virus vaccine. This implies that the effective antigenic mass of virus antigen produced by the host is roughly proportional to the vaccine dose, i.e., the same number of multiplication cycles has taken place until virus reproduction was stopped by the appearance of antibodies in the blood.
From antibody measurements it appears that, in groups showing 50% survival, the serum titer of the group, determined by extrapolation from the dose-response curve, is approximately 1 to 5 HAIU. This corresponds to the serum titer causing 50% protection against i.p. challenge in a passive immunization test (4) . As blood samples were collected 1 day before challenge, it is almost certain that survival of an i.p. challenge depends on circulating antibodies elicited by the immunization procedure.
In immunizations with live vaccine it is probable that differences in ED50 values for different routes only represent a difference in probability to reach a suitable target cell to start a successful replicative cycle. The probability of replication seems higher in the respiratory tract (ED50 140, 188) than in the peritoneum (ED, , 607 Considering all of this, a study of the primary multiplication site appears necessary for the interpretation of the data obtained.
By comparing Fig. 2A , D, E, and F, it appears that the degree of protection against a lethal infection depends only on the method of immunization and not on the challenge route. The protective ED50 values are the same, irrespective of whether vaccination and challenge were given by the same or by different routes: no additional protection is provided by local immune reactions.
After respiratory immunization with live EMC virus vaccine, lower ED50 values are obtained than after i.p. immunization. With inactivated vaccine (4) the situation is reversed, the i.p. route is more effective than the respiratory route. It follows that, after i.p. administration of a fixed antigen dose, antibody production is higher than after respiratory vaccination, but reproduction of vaccine virus is better in the respiratory tract. The same conclusion can be drawn from the antibody response data.
Local production of secretory immunoglobulin (Ig) A antibodies is frequently used as an argument in favor of respiratory immunization.
Indeed Fazekas de St. Groth (11) has shown that protection against influenza virus infection correlated better with the development of a local immune response than with circulating antibody titers in the blood. This means that circulating antibodies alone are not sufficient for total protection. However, this does not hold true for all respiratory immunization-respiratory infection systems. In the case of adenovirus, serum antibodies provide protection against virus infection and illness (7) . For picornaviruses the situation is more complex. For rhinovirus, resistance to illness is based on local antibodies (17, 18) , and for poliovirus a systemic immunity will provide full protection although local immune mechanisms are able to suppress virus growth in the respiratory and alimentary tract. Prato and Akers (19) have shown that aerosol immunization induces resistance against a lethal respiratory challenge with EMC virus, but it was not determined if local immunity played a substantial role in this protection. From our results it may be concluded that protection against respiratory EMC virus infection with virulent EMC virus is not confined to the respiratory system because the brain and the myocardium are the target organs. The use of respiratory immunization to evoke a local immune reaction seems to be only necessary against infections which are limited to the respiratory tract (influenza and rhinovirus) because local IgA antibody titers are better correlated with resistance against this type of infection. When other sites are affected (adenovirus), circulating antibodies are sufficient for protection (7) . The results with EMC virus support this view.
When comparing the merits of respiratory and parenteral immunization, the effectiveness of the procedure and the occurrence of overt and hidden side reactions must be assessed. Although respiratory immunization with live vaccine results in a significantly lower ED50 value, this difference is small, and both methods evoke a long-lasting immunity, protecting the mice for years against a lethal challenge with virulent EMC virus. Sometimes side reactions occur which can be attributed to the appearance of SPF variants, which arise by mutation from the vaccine strain. In rare occasions even paralysis of the limbs may occur, but this is only seen after i.p. and never after respiratory immunization. This is in accordance with the results from infectivity studies with the three EMC virus variants administered by various routes which will be published later.
